Biomea Fusion Stock (NASDAQ:BMEA)
Previous Close
$2.90
52W Range
$1.29 - $13.07
50D Avg
$1.93
200D Avg
$4.96
Market Cap
$71.76M
Avg Vol (3M)
$2.17M
Beta
-0.25
Div Yield
-
BMEA Company Profile
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.